Pfizer, Tempus collaborate on cancer drug development
Mobi Health News
MARCH 2, 2023
The multinational pharma company will access Tempus' AI-enabled data library to further therapeutic development and advance its portfolio in oncology.
Bipartisan House Task Force releases report on AI innovation
Mobi Health News
DECEMBER 26, 2024
Among the key findings: AI's use in healthcare may reduce administrative burdens and hasten drug development and clinical diagnosis. However, the report notes that the lack of ubiquitous, uniform standards for medical data and algorithms obstructs system interoperability and data sharing.
Drug Development 
216
216 Join 48,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Webinars
Bridging Innovation & Patient Care: The Growing Role of AI
What Your Financial Statements Are Telling You—And How to Listen!
Trending Sources
How telemedicine is increasing diversity in clinical trials
KevinMD
MARCH 14, 2019
An important part of advancing medical research and drug development is making participation in clinical trials easier and more inclusive. To develop treatments that work on men, women, and children of all ages and different ethnicities we need to have clinical trial data that represents our diverse population.
Telemedicine 419
419 
New Flagship Pioneering drug development company exits stealth mode
Mobi Health News
OCTOBER 1, 2020
Valo Health’s Opal Computational Platform uses machine learning, cloud computing and real-world data to assist in the drug discovery and development process.
Drug Development 215
215 Drug Development 215
215 
New Data Reveals Decentralized Clinical Trials Linked to Improved Diverse Participation Across Many Underrepresented Demographics
Digital Health Global
JANUARY 28, 2025
a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of Drug Development (CSDD)s PACT Consortium links decentralized clinical trial (DCT) approaches to notably higher participation rates across multiple demographic groups. PALO ALTO, Calif.–(BUSINESS
Pharma – 2025 Health IT Predictions
Healthcare IT Today
JANUARY 3, 2025
This transformation will particularly benefit organizations that can effectively combine AI expertise with traditional pharmaceutical knowledge, creating new competitive advantages in drug development efficiency, cost management, and market responsiveness.
Health IT 91
91 
Daewoong Pharmaceutical revolutionizes drug development with AI-Driven DAISY system
Digital Health Global
MARCH 28, 2024
Daewoong Pharmaceutical , a prominent player in the South Korean pharmaceutical industry, has unveiled its groundbreaking drug development system, Daewoong AI System (DAISY). Daewoong aims to leverage AI technology to reduce the drug development period to seven years and costs to approximately 600 billion won ($450 million).
Accenture Invests in QuantHealth to Accelerate Use of AI-Powered Clinical Trial Simulations to Drive Cost-Effective Drug Development
Healthcare IT Today
JANUARY 23, 2024
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,
Drug Development 121
121 
CORRECTING and REPLACING New Data Reveals DCT Components Linked to Improvements in Clinical Trial Access Among Underrepresented Communities
Digital Health Global
JANUARY 29, 2025
The updated release reads: NEW DATA REVEALS DCT COMPONENTS LINKED TO IMPROVEMENTS IN CLINICAL TRIAL ACCESS AMONG UNDERREPRESENTED COMMUNITIES Representation of Asian participants increased by six percentage points; American Indian/Alaska Native representation quadrupled; Female representation rose from 49.0% PALO ALTO, Calif.–(BUSINESS
Weekly Roundup – January 4, 2025
Healthcare IT Today
JANUARY 4, 2025
Discussing Data Quality and Migration With e4health. Krista Hawk and Todd Goughnour sat down with John Lynn to explain the challenges of improving healthcare data quality when 58% of data is in legacy systems , of which most health systems have close to 300. No hard feelings if you did – I was off for a few days, too.)
EHR 93
93 
Demystifying AI: A Review of the Fundamentals and Applications in Drug Development
ActiGraph
SEPTEMBER 3, 2024
The field of drug development is no exception. In this blog post, we'll explore the history of AI, clarify key concepts and common questions, and delve into its use in drug development.
23andMe announces major Workforce Reduction amid Financial Struggles
Digital Health Global
NOVEMBER 12, 2024
The company holds highly sensitive data about its customers, raising concerns about the future of its valuable DNA database. Despite these challenges, 23andMe remains optimistic about its prospects, reaffirming its commitment to safeguarding customer data and prioritizing privacy.
Small Language Models (SLMs) have the potential to revolutionise Healthcare AI in addition to LLMs
Lloyd Price
JANUARY 16, 2025
They are trained on massive amounts of text data, learning to predict the next word in a sequence. Enhanced Personalisation: SLMs can be trained on specific datasets, allowing them to provide personalised insights and recommendations based on individual patient data. SLMs use a similar approach to LLMs, but with a smaller scale.
Health Consumers Are Now Amazon-Primed for Healthcare – HealthConsuming Explains, Part 2
Health Populi
APRIL 29, 2019
In the past couple of months, Amazon announced many health-related plans and developments, including: Accepting medical and health savings accounts (HSAs) to pay for consumer health products like over-the-counter drugs. ” It’s about the data generated by those transactions, which help to construct profiles on you and me.
HIPAA 307
307 
Merative formerly IBM Watson Health poised to launch raft of new products in 2025
Lloyd Price
NOVEMBER 16, 2024
The new company aims to leverage its extensive data sets and technology to provide innovative solutions across various healthcare sectors, including life sciences, provider, imaging, health plan, employer, and government health and human services. MarketScan: Offering comprehensive data on healthcare costs and utilisation trends.
The next revolution in the pharmaceutical industry: the transformative potential of AI
Digital Health Global
SEPTEMBER 19, 2023
Among these transformative innovations, artificial intelligence (AI ) stands out as a major force, reshaping the fields of drug discovery , drug development, clinical trials and patient care. The effectiveness of AI in processing and decoding vast amounts of data can also be seen in patient-centred care.
Pharmaceuticals 167
167 
Quibim: $50M Series A for Precision Medicine with AI-Powered Imaging Biomarkers
Healthcare IT Today
FEBRUARY 25, 2025
This is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow health monitoring but also enhance patient stratification, improve the success rates of drug development programs, and enable treatment testing before application.
Biofourmis announces major agreements with top pharmaceutical companies
Digital Health Global
FEBRUARY 19, 2024
Centered on digital biomarker and safety monitoring algorithm development, with a specific emphasis on cytokine release syndrome (CRS) detection, the oncology programs harness cutting-edge data science and technology to elevate remote data collection, patient monitoring, and safety protocols.
Pharmaceuticals 166
166 
How AI is Shaping Drug Discovery at AION Labs
Healthcare IT Today
APRIL 25, 2024
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drug development processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
Pharmaceuticals 136
136 
Infographic: Digital Measures in Oncology Drug Development
ActiGraph
SEPTEMBER 23, 2021
Oncology is one of the most active and fastest growing areas of drug development research, outpacing other therapeutic areas in terms of study volume, complexity, cost, and duration.
Infographic: Digital Measures in Oncology Drug Development
ActiGraph
SEPTEMBER 23, 2021
Oncology is one of the most active and fastest growing areas of drug development research, outpacing other therapeutic areas in terms of study volume, complexity, cost, and duration.
Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption, Sharp Increase Compared to Study-by-Study Adoption
Digital Health Global
JANUARY 28, 2025
In related news, Medable announced new data from the Tufts Center for the Study of Drug Development (CSDD)s PACT Consortium that links decentralized clinical trial approaches to higher participation rates across multiple demographic groups. in DCT-enabled studies.
Life Science 88
88 
Healthcare AI Tools – 2025 Health IT Predictions
Healthcare IT Today
JANUARY 7, 2025
This means AI will be embraced incrementally, first to assist in data processing, workflow automation, and patient outreach, laying the groundwork for eventual clinical applications. This gradual, strategic approach helps systems build trust and confidence in AI’s role as a supportive force in healthcare.
Health IT 93
93 
A roadmap by the FDA for incorporating digital health technologies in clinical trials
Digital Health Global
MARCH 30, 2023
The FDA has announced several guidelines and plans to hold at least one public meeting on digital health technologies (DHTs) to be used in drug clinical trials by the end of the year. Drug development process questions the reliability and accuracy of DHT products.
Digital Health 167
167 
Zephyr AI Raises $111 Million in Series A Financing
Healthcare IT Today
APRIL 25, 2024
The company is developing improved data federation tools along with various machine learning algorithms in the areas of oncology and cardiometabolic disease. The new funds will enable Zephyr AI to further enhance its analytical speed and fortify its extensive collection of training and validation data sets.
Drug Development 126
126 
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
Digital Health Global
MARCH 29, 2023
Genialis is developing next-generation patient classifiers using machine learning and high-throughput omics data to capture underlying disease biology and predict how patients will likely respond to targeted therapies. ResponderID yields new biomarkers for drug development and discovery programs, as well as diagnostic tests.
Drug Development 128
128 
Enriching RWE with Novel Data Sets: How Medical Imaging Data Can Accelerate Drug Development
hea!thcare innovation - Clinical IT
MAY 16, 2019
Real-world evidence has the potential to be especially valuable in a number of healthcare use cases
Healthcare AI Bias: Reasons and Resolutions
Healthcare IT Today
APRIL 14, 2022
Artificial intelligence (AI) holds great promise to dramatically improve clinical outcomes for patients, but in a perverse twist, AI algorithms that are used to improve drug development and support healthcare don’t just highlight social inequities — they may ultimately exacerbate them. A lingering […].
Drug Development 139
139 
Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape
Healthcare IT Today
MARCH 3, 2025
As the only major provider offering fully integrated CRO services and in-house trial management technology, Lindus Health is uniquely positioned to leverage big data and AI. That doesn’t just lead to faster trials, it changes the way companies can think about drug development going from waterfall big bets to agile research.”
Life Science 85
85 
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI
Healthcare IT Today
DECEMBER 6, 2024
Investments will Support New Product Offerings, US Expansion, and Development of Pathology Foundation Models Aignostics , a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insights, announced today that it has raised $34 million in Series B financing.
Life Science 76
76 
Cornerstone AI Raises $5 Million Seed to Solve Healthcare’s Data Problem
Healthcare IT Today
JULY 25, 2022
Cornerstone’s Enterprise platform launches to unlock the power of clinical data in a fraction of the time of traditional methods. Today, Cornerstone AI, a new company solving healthcare’s data challenges to improve research and care, publicly launched its first-of-its-kind AI platform.
Life Science 98
98 
The 4 Big Gaps in HealthTech: Funding, Trust, Evidence, Valuation
Lloyd Price
OCTOBER 28, 2024
Risk Aversion: Investors may be hesitant to invest in early-stage healthtech companies due to the inherent risks and uncertainties associated with medical device and drug development. Invest in Data Infrastructure: Develop robust data infrastructure to facilitate data collection, integration, and analysis.
Machine Learning in Pharma: Mindbreeze InSpire
Healthcare IT Today
NOVEMBER 24, 2021
The companies are evolving in many ways, including stepping outside drug development to tryout digital treatments and using lessons from the COVID-19 pandemic to rethink production and clinical trials. Where are pharma companies investing their windfall profits?
Drug Development 132
132 
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer
Digital Health Global
APRIL 25, 2024
By combining NYPC’s expertise in proton beam radiotherapy with Koneksa’s advanced remote monitoring solutions, the results from this study will advance our understanding of how patient-generated health data can improve radiotherapy treatment protocols in lung cancer.” The study, led by principal investigator Nitin Ohri, M.D.,
Health Data 88
88 
Cognitive Architecture: emerging computational frameworks are 'one to watch in HealthTech 2025'
Lloyd Price
FEBRUARY 9, 2025
In HealthTech, this translates to AI systems that can: Understand and interpret complex medical data: This includes everything from patient records and medical images to genomic information and real-time sensor data from wearables. Greater focus on ethical considerations: Including data privacy, bias, and transparency.
Digital Healthcare Transformation: Improving Patient Experience and Outcomes
Digital Health Global
MAY 10, 2023
Enhancing outcomes for patients with the implementation of digital technologies, such as artificial intelligence (AI) and big data analysis, empowers healthcare professionals to make better-informed decisions. Artificial Intelligence is utilized in various areas of healthcare, ranging from drug development to medical image analysis.
Future HealthTech Valuations in 2025: A Dynamic Landscape
Lloyd Price
DECEMBER 2, 2024
Focus on Data and Analytics: Companies with robust data analytics capabilities and insights into patient behaviour will be well-positioned. Data Privacy and Security: Stricter data privacy regulations will impact valuations, as companies must invest in robust security measures.
Medable and Masimo Partner to Bring Best-in-Class Wearable Devices to Clinical Research, Capturing Rich Subjective and Objective Data
Digital Health Global
MAY 29, 2024
With this partnership, Medable also enables both subjective data capture – via humans through Medable’s eCOA+ solution – and objective data capture via Masimo’s connected sensors for multifaceted, deeper data analysis in trials. And, Medable’s flexible platform enables scalability and data aggregation for a holistic approach.”
How can Palantir win 'hearts and minds' to deliver the NHS England Federated Data Platform?
Lloyd Price
NOVEMBER 21, 2023
Exec Summary: To win the hearts and minds of the public in England and successfully deliver the NHS Federated Data Platform (FDP), Palantir should focus on the following strategies: Address Privacy Concerns: Public trust is paramount, particularly when dealing with sensitive patient data. Visit www.nelsonadvisors.co.uk
Digital Health Technologies in Clinical Trials
Digital Health Global
NOVEMBER 30, 2023
Digital Health Technologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings. It improves subject engagement and communication, as well as streamline the collection of real-world and quality-of-life data.
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
Healthcare IT Today
NOVEMBER 1, 2022
Financing will be used to accelerate and further diversify COTA’s oncology real-world data products and services. an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management , a healthcare investment firm. COTA, Inc. ,
Life Science 105
105 
Reducing Disparities and Promoting Health Equity in Underserved Communities with Social Determinants of Health
Healthcare IT Today
JANUARY 22, 2025
Access to care can be optimized by effective use of data enabled by technology to provide individualized insights about patient needs, allowing for proactive interventions and better coordination of services. This approach makes healthcare more accessible and equitable for all patients.
EHR 82
82 
Patients and Industry: Starting Our New Life Together in 2023
Society for Participatory Medicine
FEBRUARY 1, 2023
The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. This hasn’t been made clear yet due in part to the fourth and final guidance session on clinical outcome assessment data yet to occur in 2023.
BioTech 112
112 
The rise of mHealth and the convergence of medicine with AI and Big Data
Lloyd Price
FEBRUARY 20, 2020
This report will explore the rise of mHealth and the convergence of medicine with AI and Big Data. Interestingly, the future of DTx may lie in cooperation rather than in competition with Big Pharma and drug development. At Mangrove, we believe digital health represents one of the very largest opportunities for value creation.
mHealth 85
85 
Let's personalize your content